Starch/Poly(glycerol-adipate) Nanocomposites: A Novel Oral Drug Delivery Device by Vestri, Ambra et al.
coatings
Article
Starch/Poly(glycerol-adipate) Nanocomposites: A
Novel Oral Drug Delivery Device
Ambra Vestri 1,†, Amanda K. Pearce 2,† , Robert Cavanagh 3, Ioanna D. Styliari 4 ,
Carlos Sanders 3, Benoit Couturaud 5 , Silvia Schenone 6, Vincenzo Taresco 1,
Rasmus R. Jakobsen 7 , Steven M. Howdle 1, Francesca Musumeci 6,* and
Domenico Sagnelli 1,*
1 School of Chemistry, University of Nottingham, University Park, Nottingham NG7 2RD, UK;
Ambra.Vestri@nottingham.ac.uk (A.V.); Vincenzo.Taresco@nottingham.ac.uk (V.T.);
steve.howdle@nottingham.ac.uk (S.M.H.)
2 School of Chemistry, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK;
a.k.pearce@bham.ac.uk
3 School of Pharmacy, University of Nottingham, University Park, Nottingham NG7 2RD, UK;
Robert.Cavanagh1@nottingham.ac.uk (R.C.); Carlos.Sanders-Velez@nottingham.ac.uk (C.S.)
4 School of Life and Medical Sciences, University of Hertfordshire, College Lane, Hatfield AL10 9AB, UK;
i.d.styliari@herts.ac.uk
5 Institut de Chimie et des Matériaux Paris-Est (ICMPE), Systèmes Polymères Complexes, UMR CNRS 7182,
2-8 rue Henri Dunant, 94320 Thiais, France; couturaud@glvt-cnrs.fr
6 Department of Pharmacy, University of Genoa, Viale Benedetto XV 3, 16132 Genoa, Italy;
schenone@difar.unige.it
7 Department of Food Science, Faculty of Science, University of Copenhagen, Rolighedsvej 26,
1958 Frederiksberg C, Denmark; rasmus@food.ku.dk
* Correspondence: francesca.musumeci@unige.it (F.M.); domenico.sagnelli@nottingham.ac.uk (D.S.)
† Ambra Vestri and Amanda K. Pearce contributed equally to this work.
Received: 17 January 2020; Accepted: 29 January 2020; Published: 1 February 2020


Abstract: Biocompatible and bio-based materials are an appealing resource for the pharmaceutical
industry. Poly(glycerol-adipate) (PGA) is a biocompatible and biodegradable polymer that can
be used to produce self-assembled nanoparticles (NPs) able to encapsulate active ingredients,
with encouraging perspectives for drug delivery purposes. Starch is a versatile, inexpensive, and
abundant polysaccharide that can be effectively applied as a bio-scaffold for other molecules in order
to enrich it with new appealing properties. In this work, the combination of PGA NPs and starch
films proved to be a suitable biopolymeric matrix carrier for the controlled release preparation of
hydrophobic drugs. Dynamic Light Scattering (DLS) was used to determine the size of drug-loaded
PGA NPs, while the improvement of the apparent drug water solubility was assessed by UV-vis
spectroscopy. In vitro biological assays were performed against cancer cell lines and bacteria strains
to confirm that drug-loaded PGA NPs maintained the effective activity of the therapeutic agents.
Dye-conjugated PGA was then exploited to track the NP release profile during the starch/PGA
nanocomposite film digestion, which was assessed using digestion models mimicking physiological
conditions. The collected data provide a clear indication of the suitability of our biodegradable carrier
system for oral drug delivery.
Keywords: starch; nanoparticles; drug delivery; polymer; poly(glycerol-adipate); biomaterial;
biocompatible; nanocomposites
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1. Introduction
Nanostructured polymers are finding increasing use in pharmaceutical research for the
development of drug delivery systems. Nano-delivery systems can be achieved with natural or
synthetic polymers, however, synthetic polymers often have critical drawbacks, such as a lack of
biodegradability and biocompatibility, with implications of inflammation and toxicity [1]. In this
regard, poly(glycerol adipate) (PGA) is a valid synthetic solution. PGA is an enzymatically synthesized
polymer that has been shown to be a green, biodegradable, and biocompatible macromolecule. It has
an amphiphilic balance within the repetitive unit that aids with the production of self-assembled
nanoparticles (NPs) by nanoprecipitation in water [2]. Moreover, the PGA suitability for drug delivery
carrier development has previously been explored. For example, PGA was used as a drug delivery
device of indomethacin. In particular, the polymer was grafted with the drug producing a novel
composite. This grafted PGA could self-assemble into NPs and act as a drug “cargo” for a controlled
delivery system [2–4].
Oral drug delivery systems are an important strategy to achieve more effective formulations,
especially those concerning poorly bioavailable drugs, such as Biopharmaceutical Classification
System (BCS) class II compounds, which are defined as highly permeable but poorly aqueous soluble
molecules [5]. In this case, the role of the carrier systems is to increase the apparent water solubility of
the drug in order to improve its bioavailability. This process can be limited by an earlier instability of
the carrier, causing an unwanted drug precipitation in the body fluids before it can reach the proper
site of absorption [6]. The combination of nanostructured drug carriers with polymeric matrices could
represent an innovative and effective approach to overcome this limitation.
Interestingly, the NPs produced with PGA show high-stability when embedded in complex
polymeric semi-crystalline matrices [3]. One example of these matrices is starch, the most abundant
polysaccharide on the earth [7–9]. Starch is a polymer composed of two macro-molecules: amylose
and amylopectin. Amylopectin is a much larger branched polymer than amylose and represents
approximately 75% of starch. Amylose instead is a linear polymer composed by α-(1-4) linked glucose
units [8,10]. Recently, it was demonstrated that starch is a suitable vector for the transport of PGA
NPs [3]. It was proposed that starch could trap NPs in its crystalline phase after producing the casted
films, which should allow a more controlled release of a drug. Furthermore, starch films produced
with and without NPs stimulated the growth of intestinal cells.
For all these reasons, we sought to develop a novel oral drug delivery system consisting of native
barley starch blended with PGA NPs in order to obtain a biocompatible nanocomposite to improve the
apparent water solubility of drugs.
Kinase inhibitors (KIs) are a class of drugs whose application in cancer treatment is constantly
growing. Indeed, 49 KIs have been approved by the FDA over the last 20 years [11,12] and more than
2000 clinical trials evaluating these compounds are ongoing [13]. KIs, blocking specific enzymatic
pathways that are hyper activated in tumors, have paved the way for better tolerated and targeted
cancer therapies [14]. Although small molecule KIs can generally be orally administered [12] with
remarkable advantages for patient treatment, they are often affected by a poor pharmacokinetic profile.
This can lead to variations in plasma concentration, insufficient levels of the drug at the site of action,
variability in systemic response, and other hardly controllable answers that can compromise the efficacy
of therapy [15]. For these reasons, many strategies, such as the preparation of prodrugs, polymeric
NPs, or liposomes, have been already developed or are under investigation in order to overcome this
KI intrinsic limit [16].
Schenone et al. have reported a wide library of potent KIs endowed with a pyrazolo[3,4-d]
pyrimidine scaffold [17,18]. Many of these compounds are active on different cancer cell lines, and some
also showed activity in in vivo mouse models [19,20]. Among the members of this library, compound
SI214 (Figure 1a) is a potent Src inhibitor (Ki = 90 nM) and possesses a considerable antiproliferative
effect on the SH-SY5Y Neuroblastoma cell line (IC50 = 80 nM). Despite these promising biological data,
SI214 has low solubility in water (0.12 g/mL), which prevents its oral administration [21]. It has been
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successfully demonstrated that solid dispersions of pyrazolo[3,4-d]pyrimidine analogous containing
an hydrophilic polymer as inert carrier possess an increased apparent water solubility due to enhanced
interactions between the hydrophilic polymeric chain and the hydrophobic drug scaffold leading. It was
further shown that the polymer–drug interactions led to the nano-microaggregates of the formulations
assembling themselves [22]. For this reason, we selected SI214, as a pyrazolo[3,4-d]pyrimidine model,
for the following study.
Furthermore, evidence shows that the pyrazolo[3,4-d]pyrimidine nucleus can be a valuable
scaffold to develop antimicrobial agents [23–25] and thus we additionally evaluated this compound
against a series of strains of S. aureus and E. coli.
To further validate our work, we extended the in vitro evaluation to Camptothecin (CPT)
(Figure 1a), a topoisomerase I inhibitor, whose activity as anticancer agent is confirmed [26] and
efficacy as antimicrobial drug has been recently investigated [27]. CPT, as with SI214, suffers from low
solubility in water and, in addition, is characterized by poor stability [28,29].
Therefore, in the present study, starch/PGA nanocomposites were characterized for the oral
drug-delivery of SI214 and CPT molecules as anticancer and antimicrobial agents. A systematic study
of encapsulation, via solubility enhancement UV-vis evaluation, was performed and showed that the
NPs increased the apparent solubility in water of the drugs of several order of magnitudes compared to
the pure drugs. Then, the stability profile of starch-NP nanocomposites was evaluated upon exposure
to conditions mimicking the human gastrointestinal (GI) environment: the PGA was grafted with a
fluorophore (Cy5) and the NP release from the matrix starch was monitored in a dynamic in vitro
model simulating the human digestion. The formulations tuned the release of the NPs, demonstrating
the feasibility of our novel system as an edible nanocomposite.
2. Materials and Methods
2.1. Materials
All the chemicals used in this work were purchased from Sigma-Aldrich (Saint Louis, MO, USA)
unless otherwise stated. Altia Industrial (Koskenkorva, Finland) kindly supplied the barley starch.
Caco-2 human epithelial colorectal adenocarcinoma cells were obtained from the American Type Culture
Collection (ATCC; Manassas, VA, USA), and were used between passages 30-35 and HCT116 colorectal
cancer cells were obtained from AMS Biotechnology (Abingdon, UK). S. aureus (SA01, SA02) and E. coli
(EC07, EC19) bacteria were obtained from AMS Biotechnology (Europe). The PrestoBlue cell viability
assay was purchased by Thermo Fisher Scientific (Waltham, MA, USA). Compound SI214 was synthesized
as previously described [21]. CPT was purchased from Cambridge Bioscience (Cambridge, UK).
2.2. Methods
2.2.1. PGA and Cy5-PGA Synthesis
PGA was enzymatically synthesized from divinyl adipate and glycerol in tetrahydrofuran (THF)
at 40–45 ◦C by a lipase immobilized on acrylic beads (Novozyme 435), as described by Sagnelli et al. [3].
PGA-Cy5 (PC) conjugate was synthesized via the direct coupling of amino-Cy5 to the free carboxylic
end group of the polymer by carbonyldiimidazole mediated reaction. After purification via multistep
precipitations and dialysis, against a mixture of water and methanol, the degree of coupling was
assessed by UV-vis measurement.
2.2.2. PGA NP Preparation and Characterization by Dynamic Light Scattering (DLS)
PGA NPs were produced by the solvent displacement technique, also called nanoprecipitation [30].
We used acetone (2 mL) as an organic solvent to dissolve the polymer and ultrapure water (10 mL) as a
non-solvent system to achieve the NP formation. The PGA polymer (15 mg) dissolved in acetone was
dropped into the water (1.5 mg/mL PGA in the aqueous medium) under constant magnetic stirring
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(550 rpm) at Room Temperature (RT) (19 ◦C). The mixture was left overnight in a fume hood while
being agitated to let evaporate the organic phase. Blue PGA NPs were produced in the same way,
but with a 1:5 (w/w) mixture of PC and PGA, in order to reach a total final polymer concentration of
1.5 mg/mL in water. Likewise, the drug loaded NPs were obtained with the same nanoprecipitation
technique, dissolving both the polymers and the drug in the organic phase. In this case, the drug was
in a 1:5 (w/w) ratio respect to PGA.
The different formulations in ultrapure water (1.5 mg/mL) were characterized by DLS (Zetasizer
Nano ZS, Malvern Instruments, Malvern, UK). Measurements in triplicate were used to calculate
average intensity particle size distributions.
2.2.3. Casting of Films
The films were prepared in order to reach a final starch surface density of 10 mg/cm2, taking into
account the native water content (%w) of starch [3]. The blue PGA NPs were 3% of starch (dry weight,
d.w.). The starch was suspended in ultrapure water and the mixture was heated under magnetic stirring
in an oil bath at 95 ◦C for ≈20 min, until complete starch melting was achieved. Then, the solution was
rapidly cooled in an ice bath up to a temperature of 50 ◦C before mixing a proper volume of NPs and
perform the casting. For the negative control (blank), an equal volume of ultrapure water with respect
to the NPs suspension was mixed to the 50 ◦C starch solution. The films were prepared by casting in
teflon-coated petri dishes and dried at 50 ◦C in a ventilated oven.
2.2.4. In vitro Static Digestion of Starch/Blue PGA Nanocomposites
A simplified static in vitro digestion method was used, as reported by Sagnelli et al. [31]. Simulated
Salivary Fluid (SSF: 15.1 mM KCl, 13.6 mM NaHCO3, 0.75 mM CaCl2, pH 7), Simulated Gastric Fluid
(SGF: 6.9 mM KCl, 47.2 mM NaCl, 12.5 mM NaHCO3, 0.075 mM CaCl2, pH 2), and Simulated Intestinal
Fluid (SIF: 6.8 mM KCl, 38.4 mM NaCl, 85 mM NaHCO3, 0.3 mM CaCl2, pH 7) were used to mimic
the physio-chemical human gut conditions, and they were freshly prepared before use. Starch/blue
PGA nanocomposites and plain starch films (negative control) were cut into small pieces in order to
simulate the oral mastication. A total of 0.5 g (dry weight, d.w.) of chopped and SSF at a 1:2 (w:w)
ratio was incubated under shaking conditions (170 rpm) at 37 ◦C for 1 min. An equal volume of SGF
supplemented with fungal lipase (in SGF 60 IU/mL) and porcine pepsin (in SGF 1200 IU/mL) was
added to the bolus to mimic the gastric phase (incubation for 30 min, at 37 ◦C, at 170 rpm shaking
speed). In the intestinal phase, SIF solution with pancreatic α-amylase (in SIF 200 IU/mL) as porcine
pancreatin 8X (L3126 Sigma-Aldrich) was added at a 1:1 (v:v) ratio with respect to the chyme volume,
and the samples were incubated for 17 h (37 ◦C, 170 rpm shaking speed). Triplicate aliquots (70 µL)
were taken at different time points (0, 30 min, 1 h, 2 h, 17 h) and replaced with an equal volume of
fresh SIF. The collected aliquots were dropped in 70 µL of 99% ethanol and snap frozen in liquid N2 to
interrupt the digestion [31].
2.2.5. Dynamic Digestion
A dynamic in vitro model called The Smallest Intestine (TSI) was used, as described by
Cieplak et al. [32]. Briefly, the TSI allows us to modulate the physiochemical conditions (pH, bile,
and gastric enzymes) through the human stomach and small intestine (SI), exploiting dialysis to
simulate absorption and using a consortium of SI bacteria to simulate a healthy ileal microbiota. Five
stirred batch-like reactors useable in parallel constitute the whole TSI unit, and each reactor (with
a working volume of 12 mL) mimics one person’s SI. Specifically, the reactors are able to simulate
the stomach, duodenum, jejunum, and ileum passage under controlled conditions (temperature, pH,
anaerobic environment). The stomach passage (fasted state, pH = 2) was simulated as lined out
previously [32] for 30 min using 1 g of nanocomposite (starch/blue PGA films or plain starch films as
negative control). After 30 min in stomach conditions, the duodenum step started (30 min), followed
by the jejunum (300 min) and ilium (120 min) passage [32].
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Simulated Salivary Fluid (SSF), simulated gastric fluid (SGF), and simulated intestinal fluid
(SIF) [30] devoid of sodium bicarbonate were used to mimic the electrolyte composition and osmotic
pressure occurring in the human GI tract, as reported by Cieplak et al. [32]. The experiment was
conducted in fasted state at 37 ◦C. The TSI reactors were filled with 1.4 mL SSF (PH 7), 2.3 mL of SGF
(pH 3) and pepsin solution (pepsin activity of 2000 U/mL in the final volume), 1.4 mL of water, and
1 g of nanocomposite (starch/blue PGA films or plain starch films as negative controls). After 30 min,
4.5 mL of SIF, 10 µL of 0.6 M CaCl2, pancreatic juice as a mixture of SIF and porcine pancreatin 8X
(trypsin activity of 40 U/mL in the final volume), and the bile solution (4 mM bile acids in the final
volume) were added to simulate the duodenum. During the duodenal passage, a pH steady increment
from 6 to 6.8 was achieved. Dialysis cassettes (Slide-A-Lyser G2, ThermoScientific) with a cut-off of
10 kDa were used to simulate the absorption of electrolytes, small nutrients, and bile during jejunal
digestion, and the pH was elevated from 6.8 to 7.2. Fresh SIF (pH 7.2) supplemented with SI microbiota
(107 CFU/mL in the reactor) was added with a chyme to SIF ratio of 50:40 (v/v) to simulate the ileum
stage (pH 7.2). During the 7 h digestion, duplicate samples (70 µL) were taken at different time points
for two biological replicates and the negative control (Stomach: 0 min, 30 min; Duodenum: 60 min;
Jejunum: 180 min, 300 min; Ileum: 420 min). The collected samples were dropped in one volume of
99% ethanol and snap frozen in liquid N2 to interrupt the digestion.
2.2.6. NP Release Profile Evaluation
Aliquots collected during the static/dynamic digestion experiments were defrosted in ice and then
centrifuged at 4000 rpm and 4 ◦C for 10 min. The supernatants were plated in 96 well plates and the
UV absorbance at 650 nm was recorded. The calibration curve of blue PGA NPs was constructed and
used to calculate the cumulative percentage release of NPs over time.
2.2.7. Cell Culture Conditions
Cells were routinely cultured in a growth medium at 37 ◦C with 5% CO2 in 75 cm2 culture flasks
until 70% confluency was achieved. The Caco-2 cell growth medium consisted of Dulbecco’s Modified
Eagle Medium (DMEM) supplied with 10% (v/v) Fetal Bovine Serum (FBS), and 2 mM L-glutamine.
HCT116 cells were cultured in McCoy’s 5a medium containing 10% (v/v) FBS.
2.2.8. Cytotoxicity of Study Formulations
The PrestoBlue cell viability assay (Thermo Fisher Scientific) was performed to assess NP
cytotoxicity via the measurement of cellular metabolic activity. The Caco-2 cells were seeded at
1 × 104 cells/well in 96 well plates and HCT116 cells were seeded at a density of 2 × 104 cells/well.
The cells were cultured for 24 h prior to assaying. Formulations were applied to cells in a growth
medium containing 10% (v/v) FBS at NP concentrations of 0.5 mg/mL. Triton X-100 (TX-100) applied at
1% (v/v) was used as a cell death (positive) control and a vehicle control containing no NPs used as a
negative control. After 48 h of exposure, the cells were washed twice with warm PBS and 100 µL 10%
(v/v) PrestoBlue reagent diluted in a phenol red free medium applied per well for 60 min. The resulting
fluorescence was measured at 560/600 nm (λex/λem). Relative metabolic activity was calculated by
setting values from the negative control as 100% and positive control values as 0% metabolic activity.
2.2.9. Minimum Inhibitory Concentration (MIC)
The in vitro antimicrobial activity of study formulations was performed against two strains of
gram-positive S. aureus (SA01, SA02) and two strains of gram-negative E. coli (EC07, EC19) bacteria.
The MIC was determined via broth microdilution assay. Formulations were prepared at a concentration
of 1000 µg/mL in Luria Bertani (LB) broth, and free drug was prepared at a concentration of 250 µg/mL
in LB broth. An overnight culture was grown from a single colony in 10 mL LB broth at 37 ◦C in an
incubator at 180 rpm overnight. A subculture was prepared by diluting the overnight culture 1:100
and then 1:20 in LB broth and was finally adjusted to 5 × 106 CFU/mL by optical density at 600 nm.
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A two-fold dilution series of 50 µL of test solution was added into U-bottom 96 well plates followed by
the addition of 50 µL of bacteria subcultures. Positive (without test compound) and negative (without
bacteria or test compound) were included in all experiments. MIC values were defined as the lowest
concentration of test compound that showed no visible growth after overnight incubation at 37 ◦C.
2.2.10. Molecular Dynamics simulations (MD)
The models and forcefield parameters for the study of the interactions were developed as follows:
first, the structures of the drugs and dimers of the polymers (PGA, PGA-Me) were created using
ChemDraw3D. The structures were submitted to the online Automated Topology Builder (ATB)
tool [33,34] that provided appropriate parameters for use with the GROMOS54a7 [35,36] force-field.
The systems were composed by placing a dimer and a single drug molecule in a box and solvating the
system (SPC water model [37]). After solvation, the atoms were relaxed by 10,000 steps of EM with
the steepest descent algorithm followed by an equilibration via NVT ensembles at 298 K (V-rescale
thermostat) for 100 ps and then in an NPT ensemble at 1 bar (Berendsen barostat). Bonds to hydrogen
atoms were constrained to allow a time step of 2 fs. All of the MD simulations were run with the same
barostat and thermostat under PBC. Long-range electrostatics were treated with PME [38,39].
3. Results and Discussion
3.1. NPs’ Formation and Drug Water Solubility Enhancement
PGA, PGA-CTP, and PGA-SI214 NPs were formulated via simple nanoprecipitation technique,
using acetone as the organic phase. A DLS screening assay and zeta potential analysis were performed
in order to fully characterize the NPs (Table 1).
Table 1. Size distribution, polydispersity index, and zeta potential data of the produced nanoparticles
(NPs).
Size (nm) PdI Z-potential (mV)
PGA 175.0 ± 1.9 0.033 −12.0 ± 0.5
PGA-SI214 172.3 ± 1.8 0.030 −15.2 ± 0.9
PGA-CPT 184.1 ± 2.0 0.027 −17.6 ± 0.5
Both bare and loaded PGA NPs showed comparable sizes (range size: 172.3–184.1 nm), and a very
narrow size distribution (PdI < 0.033). These data indicated a similar packaging for plain PGA and
PGA-SI214 or PGA-CPT (Figure 1a) and a good quality of NPs, respectively. Furthermore, the negative
surface charge of NPs (negative zeta potential), due to the free OH of the PGA, conferred NPs stability
in an aqueous environment [40–42].
Analysis of the variation of the absorbance between the free drugs in water and their PGA
formulation was assessed by UV-vis spectroscopy [22] and revealed an enhancement of the apparent
water solubility of both compounds after encapsulation (Figure 1b).
PGA-SI214 exhibited a higher ∆A% than PGA-CPT. This is likely because SI214 is able to form
more interactions with PGA than CPT, as supported by DLS study that showed a higher contraction of
the size for the pyrazolo-pyrimidine derivative compared to the alkaloid (size of PGA-SI214 < size of
PGA-CPT).
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3.2. All Atom Molecular Dynamics (MD) Simulation
All atom molecular ynamics (MD) simulations are attracting attention in the polymer-based
drug delivery field as a tool to enlighten the interactions taking place at an atomistic level [43–45].
Our 10 ns MD simulations for the interactions between the dimers of PGA and the two drugs were used
to evaluate the distance between the moieties and the possible formation of hydrogen bonds. Multiple
H-bond formation was observed in the PGA-SI214 simulation (Figure 2a,b), while no H-bonding
formation was observed in the PGA-CPT simulation (Figure 2c,d). These preliminary computational
data can be used to corroborate the different experimental enhanced apparent water solubilities of the
two drugs when formulated with the polymer (Figure 1b). In fact, as can be seen from Figure 1b, SI214
∆A% improved twofold compared to the CPT, hinting to a better interaction between the polymeric
chains and the KI drug.
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HCT116 cells may be explained by the expression of oncogenes in this cell line that are absent in Caco-2
cells, such as mutant KRAS and PIK3CA genes [46–48]. These gene mutations may subsequently
confer HCT116 cells increased susceptibility to treatment with a Src tyrosine KI and CPT [49–51].
Then, to evaluate if SI214 and CPT could be developed as antimicrobial agents, we tested against
2 strains of gram-positive S. aureus (SA01, SA02) and 2 strains of gram-negative E. coli (EC07, EC19)
bacteria. The two compounds have been assayed both as free drugs dispersed in water and drug-loaded
PGA NPs. As can be noted in Table 2, no activity was detected for drugs suspended in water, while the
same Minimum Inhibitory Concentration (MIC) values have been calculated for both encapsulated
compounds towards S. aureus and E. coli, respectively.
Table 2. Minimum Inhibitory Concentration (MIC).
SA01 SA02 EC07 EC19
SI214 1 n.d. n.d. n.d. n.d.
PGA-SI214 500 µg/mL 500 µg/mL 250 µg/mL 250 µg/mL
CPT 1 n.d. n.d. n.d. n.d.
PGA-CPT 500 µg/mL 500 µg/mL 250 µg/mL 250 µg/mL
1 For drugs dispersed in water no activity was detected.
In particular, PGA-SI214 and PGA-CPT were 2-fold more potent against the two strains of E. coli
than those of S. aureus, suggesting a screening of PGA-drug NPs against a panel of gram-negative
bacteria as a possible continuation of this work.
3.4. Film Formation and NPs Entrapment
The suitability of barley starch film as bio-based coating polymer for PGA NPs has been previously
reported [3]. Tests performed on Caco-2 cells using film extracts proved the starch/PGA nanocomposite
biocompatibility. In fact, no cell membrane damage was detected, and the cell metabolic activity
seemed to be increased by the free starch content of the extracts.
Prior to the preparation of the films, the stability of PGA NPs was assessed at 50 ◦C by DLS, to
ensure NPs integrity during the film drying process. The monitoring of the NPs’ size at 50 ◦C over
24 h did not show significant changes in the NP dimension (data not shown), proving the PGA NPs’
suitability for the nanocomposite film preparation. Moreover, the PGA NPs stability in the starch
matrix was previously showed by Sagnelli et al. [3].
3.5. Blue-NPs’ Release from Film in Different Buffers
The starch/PGA nanocomposite films were characterized via a static in vitro method simulating
the physiochemical conditions of the human gut to evaluate the NP release profile over time as a
cumulative percentage. As shown in Figure 4, because of the mild hydrolysis of the starch matrix in
both SSF and SGF, only a minimal release of 8.4% was detected at the time of the SIF addiction (t0).
The small intestine represents the major site for absorption [52], and thus the starch matrix appears
to be a useful bio-scaffold to preserve the integrity of the biodegradable PGA NPs to the site of interest,
hampering PGA degradation in the oral–gastric tract. Indeed, PGA NPs are susceptible to degradation
by the different digestive enzymes that cause the polymer breakdown. Additionally, PGA NPs are
short-lived at the acidic pH of SGF [3,42]. In particular, Swainson et al. reported that the acidic pH of
SGF caused PGA NPs instability, and an important swelling in terms of PGA NP hydrodynamic size
was observed in the presence of lipase, suggesting degradation [42]. The PGA NP degradability by
lipase was further proved by Sagnelli et al., who reported a tenfold increment in NP size after a 3 h
incubation with lipase with respect to the enzyme-free NP control [3]. Undoubtedly, it is necessary to
have complete drug retention in stable NPs to ensure that the active principle perseveres its solubilized
state until reaching the absorption site in the small intestine. Drug absorption through the intestine
mucous membrane is commonly achieved once the polymeric micelles release their active content
Coatings 2020, 10, 125 10 of 15
in the gut environment [5]. In this regard, a biphasic NPs release pattern was detected during the
simulated intestinal digestion (Figure 4), with an early 42% burst release of PGA NPs in the first hour.
Then, a zero-order-like release phase seemed to take place, reaching a total release of 79% after 17 h.
The gradual drug release in the small intestine fluids from loaded PGA NPs could reasonably take
place once NPs were free from the starch matrix, as the biodegradability of the PGA NP was extensively
shown by Swainson et al. [42] using lipase, pancreatin, and other digestive enzymes.
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Dynamic mod ls have the advantage over static models t better m mic the physiological changes
occurring through the ifferent sections of the human GI tract, e.g., the dynamic variation of pH or the
absorp i process. The TSI reported by T. Cieplak et al. [32] is a small volume in vitro model w rking
under controlled temperature and an erobic conditions. The TSI is able to simulate the stomach,
duodenum, jejunum, a d ileum passages (Figure 5) using simulated gastric fluid containing digestive
enzymes and the addition/absorbtion of bile salts and in culation with a r presentativ gut microbiota
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At the end of the gastric digestion, the chyme met the SIF, the bile salts, and the pancreatic juice.
After 30 min of duodenal digestion, the apparent NP concentration reached 0.83 ± 0.31 mg/mL (≈
28% respect to the total NP content of the film) because of the sensitivity of the starch films to the
intestinal alpha-amylase. A NP concentration of 0.53 ± 0.16 mg/mL (≈ 18% respect to the total NP
content of the film) was detected in the jejunum after 2 additional hours of digestion, and at the end
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of the jejunal phase the level of NPs was 0.36 ± 0.06 mg/mL (≈ 12% respect to the total NP content
of the film). The NP concentrations during the jejunal phase were the result of the dynamic balance
between different processes. On one side, the starch bio-scaffold degrades under the action of glycoside
hydrolases with a consequent increase in NP level; on the other, the NPs are impaired due to the
presence of different peptidases, bile salts, and lipase and the subsequent dialyzation of the degraded
polymer fraction. After 7 h of total digestion, an absorbance related to 0.16 ± 0.04 mg/mL of NPs was
detected in the jejunum, the intestinal site where antimicrobial drugs can start to exert their activity.
In the future, different cross-linking levels of the starch matrix have to be tested to tune the NP release
rate in the different GI tracts, in agreement with the activity and the site of action/absorption of the
encapsulated active agent.
Interestingly, it should be noted that the data variability decreased for the time points after
the duodenum phase. This variation in data variability levels could represent a further insight into
NP breakdown. Indeed, multiple PC degradation by-products may differently result in shifts and
shape variation in the UV-Vis absorbance peak influencing the data variability, as already reported in
literature for a comparable dye-PGA conjugate [42]. This phenomenon should be mainly relevant at
the end of the duodenum phase, as the initial burst releases a multitude of PC sub-products, which are
produced by NP degradation and retained in the duodenum. Only after reaching the jujenum were the
PC sub-products dialyzed, limiting their influence on the absorbance behavior.
The ability of the starch bio-scaffold to avoid the NP impairment in the gastric tract, despite the
acidic pH and the protease activity, was herein demonstrated. Our nanocomposite system can so
improve the bioavailability of class II therapeutic agents, avoiding their precipitation in the GI fluids
and allowing their progressive release in the intestinal environment.
4. Conclusions
In this study, we developed PGA/starch nanocomposites as bio-polymeric matrix carriers for the
controlled release of hydrophobic drugs. In particular, the polymeric formulations of two drugs (i.e.,
SI214 and CPT) with low solubility in water in their native form have been tested against different
cancer and bacterial cell lines after dissolution in an aqueous medium. Interestingly, PGA-SI214 and
PGA-CPT showed a certain activity as both antineoplastic and antibacterial drugs. This efficacy can be
attributed to the enhanced apparent water solubility of formulated drugs compared to drugs alone,
as confirmed by UV-vis spectroscopy analysis. PGA NPs were subsequently embedded in starch films
to tune the release of the NPs. Indeed, the evidence shows that in vivo NP release is quite difficult
to regulate. The starch matrix preserved the integrity of the biodegradable PGA NPs until the site
of interest, hampering PGA degradation in the oral–gastric tract. This behavior has been studied by
means of static/dynamic in vitro digestion models. Overall, we developed an innovative drug delivery
system suitable for oral administration. Moving forward from this proof-of-concept study, it would be
interesting to next explore the high-throughput screening of a panel of compounds to identify potent
anticancer and/or antibacterial drugs in cell assays, with in an vivo evaluation of the most promising
inhibitors in the PGA/starch bio-polymeric matrix.
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